受控药物的CMC开发：固体形态、密闭操作与供应规划

Originally published by Crystal Pharmatech. Republished with company attribution. Original technical perspectives, references and source links are retained.

This blog examines controlled-substance development from a CMC perspective, with emphasis on how solid form, containment, and supply assumptions can begin interacting earlier than many teams expect. For controlled substances, and especially for programs that involve highly potent compounds, solid-state decisions can affect not only product quality and manufacturability, but also handling practicality and development resilience. The discussion uses methylphenidate shortage history to illustrate why technical planning and material strategy cannot always be treated as separate issues.

Why Controlled and Highly Potent Compounds Create a Different CMC Risk Profile

For controlled substances, and for highly potent compounds, the wrong solid form can create more than a product-quality problem. A form that is too fine, too dusty, too electrostatic, or too variable can quickly become a handling, containment, and execution problem as development moves beyond early feasibility. In that setting, solid-state decisions do not remain confined to stability, dissolution, or manufacturability. They begin to shape how practical the development path will be under real operating constraints.

That is the central CMC tension in these programs. The science still starts with familiar questions around solid form, particle attributes, and product performance, but the operating environment is less forgiving. When a compound is controlled, development choices are shaped not only by chemistry, but also by restricted-access handling, security requirements, and, in some cases, a less flexible supply environment. When the compound is also highly potent, occupational containment and handling considerations add another layer of complexity.

Why Solid Form Still Matters First

Controlled status does not reduce the importance of basic solid-state work. If anything, it increases the cost of getting it wrong. ICH Q6A treats particle size and solid-state form as quality-relevant when they influence drug-product performance, including dissolution, bioavailability, and stability. [1]

That becomes even more important when operational flexibility is limited. A form that looks acceptable in early screening may still create downstream problems if it generates excessive fines, shows variable hydration behavior, or is difficult to isolate reproducibly. In practice, solid form is not only a question of stability and solubility. It also influences handling, particle control, and the reproducibility of scale-up.

Why Containment Changes the Development Path

For controlled substances, containment and access control are not just facility attributes. They influence what makes a process practical. U.S. regulations require manufacturing activities involving controlled substances to be conducted in clearly defined limited-access areas under surveillance, with access restricted to personnel required for efficient operation. [2]

Once handling conditions become more constrained, poor powder behavior stops being a minor technical nuisance and starts affecting execution directly. This is why controlled-substance CMC cannot be separated cleanly into chemistry first and facility later. If crystal form, particle size distribution, or morphology create difficult handling, the issue does not remain a technical footnote. It becomes part of the process strategy. A technically acceptable form can still be the wrong development choice if it creates disproportionate burden during transfer, sampling, cleaning, or scale-up.

What Methylphenidate Shortage History Shows

Methylphenidate provides a useful real-world reminder that controlled-substance development can be shaped by more than formulation and process science alone. A 2025 analysis of U.S. shortage data for prescription stimulant products reported 26 shortages between 2001 and 2023, with methylphenidate products among those affected. The longest resolved shortage in the dataset was for methylphenidate extended-release tablets, lasting 61.6 months. The analysis also identified manufacturing delays, supply-demand mismatch, and API or raw-material constraints among the reported drivers. [3]

That does not mean every controlled-substance program faces the same supply constraints. It does mean that material planning deserves earlier attention than many teams assume. When the broader supply environment is less forgiving, yield loss, repeated rework, and batch failure can have a larger effect on development timelines than they would in a more conventional program.

A Better CMC Approach for Controlled and Potent Programs

A stronger development strategy treats three questions as linked from the start.

• ### What is the right solid form and particle profile for the intended product?

This includes the usual questions around polymorph risk, hydration state, PSD, and manufacturability.
* ### Can that form be handled reproducibly under the containment and access conditions the program will actually use?

For controlled substances, and especially for compounds that are also highly potent, development should not assume that a form that works in a low-volume feasibility setup will remain equally practical in a more constrained operating environment.
* ### Does the development plan match the real material and supply model?

For controlled-substance programs, that means making realistic assumptions about material efficiency, rework tolerance, and the broader supply conditions around the asset, rather than treating those questions as late-stage operations issues. [3]

When those three areas are addressed together, the development path is more robust. When they are handled separately, late-stage friction becomes more likely: the selected form may be difficult to handle under real operating constraints, the process may be awkward to execute, or the material plan may be less resilient than the program requires.

How Crystal Pharmatech Can Help

Crystal Pharmatech supports controlled-substance programs and highly potent compound programs by combining solid-state judgment with development work that remains practical under real operating constraints. Our Solid Form Screening and Selection platform is equipped to support Highly Potent Compounds and Controlled Substances, helping teams evaluate form, particle behavior, and manufacturability early so development decisions remain aligned with both product needs and execution realities.

References

1. International Council for Harmonisation. Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances. 1999. https://database.ich.org/sites/default/files/Q6A%20Guideline.pdf
2. Electronic Code of Federal Regulations. 21 CFR 1301.73 Physical security controls for non-practitioners. https://www.ecfr.gov/current/title-21/chapter-II/part-1301/subject-group-ECFRa7ff8142033a7a2/section-1301.73
3. Sheykhsoltan M, Drobina J, Burns MM, Fox ER, Mazer-Amirshahi M. Drug shortages for prescription amphetamine derivatives. J Pediatr Pharmacol Ther. 2025;30(2):206-211. doi:10.5863/1551-6776-30.2.206.

Read the original article and source figures